The Race to Market: Building an Efficient Discovery Engine

Jun 8 2017

Are you confident in the integrity of your data? Every day, hundreds of scientists are generating, analyzing and managing data that form the basis to discover and develop new drugs that patients are waiting for. Laboratory data forms the building blocks of the scientific work, and its quality is critical to crucial business decisions and long term success. Johnson & Johnson Innovation, JLABS (JLABS) and Janssen R&D invite you to take an in-depth look into potential quality risks in research and explore measures to improve data quality in the drug discovery processes.

From emerging startup to big pharma - your company’s reputation, intellectual property protection and decision making depends on high quality data.

Presentations will cover the following topics:

  • Journey to bringing a drug to market
  • Dilemmas in discovery – a workshop
  • Reproducibility in research
  • A quality approach within Janssen R&D

David Malwitz | Program Manager, Bioresearch Quality & Compliance , Janssen R&D read bio»
Michael Elliott | VP, Immunology Scientific Innovation, Johnson & Johnson Innovation read bio»
Marian Nakada | VP, Venture Investments, Johnson & Johnson Innovation read bio»


8:30 AM | Registration, Breakfast & Networking
9:00 AM | Journey to bringing a drug to market
  - Drug discovery process
- Internal and external stakeholders
- Opportunities and challenges
9:25 AM | Dilemmas in discovery – a workshop
  - An interactive session focusing on potential data handling dilemmas and their associated risks
10:40 AM | Discovery data integrity – a quality approach for Janssen R&D
  - Sponsorship and support
- Training approach
- Risk-based monitoring
- Phase appropriate solutions
11:00 AM | Discussion and Q&A
11:30 AM | Program Close

$35 | General Public
$20 | Student/Academic
$45 | At the door

JLABS @ LabCentral
700 Main Street
Cambridge, MA 02139

Speakers' Biographies:
David Malwitz | Manager, Bioresearch Quality & Compliance, Janssen R&D
David is responsible for the planning and execution of external strategy in the non-regulated QA domain of Bioresearch Quality & Compliance. This includes implementing key systems and processes needed to establish a risk-based audit program, operationalizing strategic quality and compliance capabilities, and recruiting the right team and network across global R&D sites to enable a successful portfolio. In addition, David supports the internal quality maintenance program by leading internal and external assessments across multiple therapeutic areas and has supported compliance integration efforts to ensure the successful alignment of acquired assets into the Janssen R&D organization. David began his career as a research scientist at Wyeth Research and Amgen. He has a M.S. in Organic Chemistry from Wright State University and B.S. in Chemistry from Cedarville University.
Connect with David:   Connect on LinkedIn

Michael Elliott | Vice President, Immunology Scientific Innovation, Johnson & Johnson Innovation
Michael is Vice President of Immunology Scientific Innovation at Johnson & Johnson Innovation, Boston. He has spent much of his career in the biotech and pharmaceutical industry, working in large and small companies.
Michael’s career wtih the Johnson & Johnson Family of Companies includes 7 years at Centocor, where he led the clinical development of Centocor’s monoclonal antibody (mAb) products in immune and inflammatory disorders. Foremost amongst these were the development and regulatory approval of the anti-TNF mAb infliximab (Remicade®) in rheumatoid arthritis, Crohn’s disease, ulcerative colitis and other inflammatory indications, and of the follow-on anti-TNF mAb, golimumab (Simponi®) in a range of rheumatic diseases. His group also led clinical development of the first-in-class anti-IL-12/23 mAb, ustekinumab (Stelara®) for the treatment of psoriasis.
More recently, Michael served as General Manager and Site Head at TransForm Pharmaceuticals, a Johnson & Johnson company focused on high throughput drug formulation, and was a member of the Johnson & Johnson Corporate Office of Science and Technology. In January 2012, he transitioned to the role of Janssen Entrepreneur in Residence at Polaris Partners, a Boston-based VC firm, where he managed a co-investment relationship aiming to build a portfolio of investments in early stage pharma and biotech companies.
Michael earned his medical degree (MBBS) and PhD from the University of Adelaide, Australia, and is a Fellow of the Royal Australasian College of Physicians. Michael has authored many peer-reviewed journal articles, reviews and book chapters in the field of cytokine immunology and protein therapeutics.

Marian Nakada | Vice President, Venture Investments, Johnson & Johnson Innovation
Marian is Vice President, Venture Investments at Johnson & Johnson Innovation – JJDC Inc. and is based in Boston. She focuses on pharmaceutical investments in East Coast companies that are in areas of strategic interest to Johnson & Johnson. Marian previously held roles at Centocor R&D, Janssen R&D, and Janssen Business Development. She has a BA in Biology from Harvard College and a PhD in Pharmacology from the University of Pennsylvania. Marian was the JJDC investor for CoStim Pharmaceuticals, Rodin Therapeutics, and Padlock Therapeutics and currently sits on the Board of Navitor Pharmaceuticals, PhaseBio Pharmaceuticals and the New England Venture Capital Association.